370 related articles for article (PubMed ID: 24961255)
1. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
Velenosi TJ; Urquhart BL
Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
[TBL] [Abstract][Full Text] [Related]
2. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease.
Weir MR; Fink JC
Curr Opin Nephrol Hypertens; 2014 May; 23(3):306-13. PubMed ID: 24670404
[TBL] [Abstract][Full Text] [Related]
3. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Thomson BK; Nolin TD; Velenosi TJ; Feere DA; Knauer MJ; Asher LJ; House AA; Urquhart BL
Am J Kidney Dis; 2015 Apr; 65(4):574-82. PubMed ID: 25453994
[TBL] [Abstract][Full Text] [Related]
4. A quantitative approach to drug dosing in chronic kidney disease.
Olyaei AJ; Steffl JL
Blood Purif; 2011; 31(1-3):138-45. PubMed ID: 21228582
[TBL] [Abstract][Full Text] [Related]
5. Patterns of medication exposures in hospitalized pediatric patients with acute renal failure requiring intermittent or continuous hemodialysis.
Rizkalla NA; Feudtner C; Dai D; Zuppa AF
Pediatr Crit Care Med; 2013 Nov; 14(9):e394-403. PubMed ID: 23965636
[TBL] [Abstract][Full Text] [Related]
6. Drug Disposition Issues in CKD: Implications for Drug Discovery and Regulatory Approval.
Tieu A; House AA; Urquhart BL
Adv Chronic Kidney Dis; 2016 Mar; 23(2):63-6. PubMed ID: 26979144
[TBL] [Abstract][Full Text] [Related]
7. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
Ladda MA; Goralski KB
Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
[TBL] [Abstract][Full Text] [Related]
8. Adverse safety events in patients with Chronic Kidney Disease (CKD).
Offurum A; Wagner LA; Gooden T
Expert Opin Drug Saf; 2016 Dec; 15(12):1597-1607. PubMed ID: 27648959
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitors in chronic kidney disease.
Olyaei A; Steffl JL; MacLaughlan J; Trabolsi M; Quadri SP; Abbasi I; Lerma E
Am J Cardiovasc Drugs; 2013 Dec; 13(6):385-98. PubMed ID: 23975627
[TBL] [Abstract][Full Text] [Related]
10. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.
Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K
J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531
[TBL] [Abstract][Full Text] [Related]
11. Drug dosing in elderly patients with chronic kidney disease.
Lassiter J; Bennett WM; Olyaei AJ
Clin Geriatr Med; 2013 Aug; 29(3):657-705. PubMed ID: 23849014
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. The effects of acute renal failure on drug metabolism.
Philips BJ; Lane K; Dixon J; Macphee I
Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):11-23. PubMed ID: 24074057
[TBL] [Abstract][Full Text] [Related]
14. Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis.
Chakraborty S; Ghosh S; Banerjea A; De RR; Hazra A; Mandal SK
Indian J Pharmacol; 2016; 48(5):586-590. PubMed ID: 27721548
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic alterations in older people with dementia.
Reeve E; Trenaman SC; Rockwood K; Hilmer SN
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):651-668. PubMed ID: 28460576
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic studies in hemodialysis patients.
Atkinson AJ; Umans JG
Clin Pharmacol Ther; 2009 Nov; 86(5):548-52. PubMed ID: 19675540
[TBL] [Abstract][Full Text] [Related]
17. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.
Roberts DJ; Hall RI
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1067-84. PubMed ID: 23682923
[TBL] [Abstract][Full Text] [Related]
18. A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.
Nolin TD
Semin Dial; 2015; 28(4):325-9. PubMed ID: 25855244
[TBL] [Abstract][Full Text] [Related]
19. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
[TBL] [Abstract][Full Text] [Related]
20. Drug dosing in chronic kidney disease.
Gabardi S; Abramson S
Med Clin North Am; 2005 May; 89(3):649-87. PubMed ID: 15755472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
